Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model

被引:78
|
作者
Bosnakovski, Darko [1 ,2 ,3 ]
Chan, Sunny S. K. [1 ,2 ]
Recht, Olivia O. [1 ,2 ]
Hartweck, Lynn M. [1 ,2 ]
Gustafson, Collin J. [1 ,2 ]
Athman, Laura L. [1 ,2 ]
Lowe, Dawn A. [4 ,5 ]
Kyba, Michael [1 ,2 ]
机构
[1] Univ Minnesota, Lillehei Heart Inst, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA
[3] Univ Goce Delcev Stip, Fac Med Sci, Stip 2000, Macedonia
[4] Univ Minnesota, Div Rehabil Sci, Dept Rehabil Med, Minneapolis, MN 55455 USA
[5] Univ Minnesota, Div Phys Therapy, Dept Rehabil Med, Minneapolis, MN 55455 USA
来源
NATURE COMMUNICATIONS | 2017年 / 8卷
关键词
FACIOSCAPULOHUMERAL MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; FIBRO/ADIPOGENIC PROGENITORS; GENE-EXPRESSION; D4Z4; CELLS; MICE; DELETIONS; REPEAT; TYPE-2;
D O I
10.1038/s41467-017-00730-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Facioscapulohumeral muscular dystrophy is a slowly progressive but devastating myopathy caused by loss of repression of the transcription factor DUX4; however, DUX4 expression is very low, and protein has not been detected directly in patient biopsies. Efforts to model DUX4 myopathy in mice have foundered either in being too severe, or in lacking muscle phenotypes. Here we show that the endogenous facioscapulohumeral muscular dystrophy-specific DUX4 polyadenylation signal is surprisingly inefficient, and use this finding to develop an facioscapulohumeral muscular dystrophy mouse model with muscle-specific doxycycline-regulated DUX4 expression. Very low expression levels, resulting in infrequent DUX4 + myonuclei, evoke a slow progressive degenerative myopathy. The degenerative process involves inflammation and a remarkable expansion in the fibroadipogenic progenitor compartment, leading to fibrosis. These animals also show high frequency hearing deficits and impaired skeletal muscle regeneration after injury. This mouse model will facilitate in vivo testing of therapeutics, and suggests the involvement of fibroadipogenic progenitors in facioscapulohumeral muscular dystrophy.
引用
收藏
页数:9
相关论文
共 43 条
  • [21] Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells
    Sarsons, Christopher D.
    Gilham, Dean
    Tsujikawa, Laura M.
    Wasiak, Sylwia
    Fu, Li
    Rakai, Brooke D.
    Stotz, Stephanie C.
    Carestia, Agostina
    Sweeney, Michael
    Kulikowski, Ewelina
    BIOMEDICINES, 2023, 11 (10)
  • [22] Nuclear bodies reorganize during myogenesis in vitro and are differentially disrupted by expression of FSHD-associated DUX4
    Sachiko Homma
    Mary Lou Beermann
    Bryant Yu
    Frederick M. Boyce
    Jeffrey Boone Miller
    Skeletal Muscle, 6
  • [23] BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells
    Amy E. Campbell
    Jonathan Oliva
    Matthew P. Yates
    Jun Wen Zhong
    Sean C. Shadle
    Lauren Snider
    Nikita Singh
    Shannon Tai
    Yosuke Hiramuki
    Rabi Tawil
    Silvère M. van der Maarel
    Stephen J. Tapscott
    Francis M. Sverdrup
    Skeletal Muscle, 7
  • [24] Deep characterization of a common D4Z4 variant identifies biallelic DUX4 expression as a modifier for disease penetrance in FSHD2
    Lemmers, Richard J. L. F.
    van der Vliet, Patrick J.
    Balog, Judit
    Goeman, Jelle J.
    Arindrarto, Wibowo
    Krom, Yvonne D.
    Straasheijm, Kirsten R.
    Debipersad, Rashmie D.
    Ozel, Gizem
    Sowden, Janet
    Snider, Lauren
    Mul, Karlien
    Sacconi, Sabrina
    van Engelen, Baziel
    Tapscott, Stephen J.
    Tawil, Rabi
    van der Maarel, Silvere M.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 (01) : 94 - 106
  • [25] AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD
    Giesige, Carlee R.
    Wallace, Lindsay M.
    Heller, Kristin N.
    Eidahl, Jocelyn O.
    Saad, Nizar Y.
    Fowler, Allison M.
    Pyne, Nettie K.
    Al-Kharsan, Mustafa
    Rashnonejad, Afrooz
    Chermahini, Gholamhossein Amini
    Domire, Jacqueline S.
    Mukweyi, Diana
    Garwick-Coppens, Sara E.
    Guckes, Susan M.
    McLaughlin, K. John
    Meyer, Kathrin
    Rodino-Klapac, Louise R.
    Harper, Scott Q.
    JCI INSIGHT, 2018, 3 (22):
  • [26] DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle
    Yao, Zizhen
    Snider, Lauren
    Balog, Judit
    Lemmers, Richard J. L. F.
    Van der Maarel, Silvere M.
    Tawil, Rabi
    Tapscott, Stephen J.
    HUMAN MOLECULAR GENETICS, 2014, 23 (20) : 5342 - 5352
  • [27] Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways
    Rickard, Amanda M.
    Petek, Lisa M.
    Miller, Daniel G.
    HUMAN MOLECULAR GENETICS, 2015, 24 (20) : 5901 - 5914
  • [28] AAV.U7-snRNA Targeting DUX4 Prevents Muscle Damage in a Facioscapulohumeral Muscular Dystrophy Mouse Model
    Rashnonejad, Afrooz
    Chermahini, Gholamhossein Amini
    Taylor, Noah M.
    Wein, Nicolas
    Harper, Scott Q.
    MOLECULAR THERAPY, 2021, 29 (04) : 292 - 292
  • [29] A Systemically Administered Unconjugated Antisense Oligonucleotide Targeting DUX4 Improves Muscular Injury and Motor Function in FSHD Model Mice
    Kakimoto, Tetsuhiro
    Ogasawara, Akira
    Ishikawa, Kiyoshi
    Kurita, Takashi
    Yoshida, Kumiko
    Harada, Shuichi
    Nonaka, Taeko
    Inoue, Yoshimi
    Uchida, Keiko
    Tateoka, Takashi
    Ohta, Tetsuya
    Kumagai, Shinji
    Sasaki, Takashi
    Aihara, Hajime
    BIOMEDICINES, 2023, 11 (09)
  • [30] Downstream events initiated by expression of FSHD-associated DUX4: Studies of nucleocytoplasmic transport, γH2AX accumulation, and Bax/Bak-dependence
    Masteika, Isabel F.
    Sathya, Anvitha
    Homma, Sachiko
    Miller, Bess M.
    Boyce, Frederick M.
    Miller, Jeffrey Boone
    BIOLOGY OPEN, 2022, 11 (02):